Showing 1 - 6 results of 6 for search 'Luca Mologni', query time: 0.02s Refine Results
  1. 1
    Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.

    Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. by Richard Junior Zapata Dongo, Diletta Fontana, Luca Mologni, Juan Enrique Faya Castillo, Stefany Fiorella Infante Varillas

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer

    Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer by Richard Junior Zapata Dongo, Diletta Fontana, Luca Mologni, Juan Enrique Faya Castillo, Stefany Fiorella Infante Varillas

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer

    An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer by Richard Junior Zapata Dongo, Julio A. Poterico, Diletta Fontana, Luca Mologni, Carla Alvarez-Chacon, Juan Rojas-Armas, Jaeson Calla

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers

    Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers by Matteo Villa, Giorgio Cazzaniga, Maddalena Bolognesi, Federica Malighetti, Valentina Crippa, Andrea Aroldi, Giorgio Bozzini, Fabio Pagni, Rocco Piazza, Luca Mologni, Daniele Ramazzotti

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer

    Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer by Valentina Crippa, Nicoletta Cordani, Alberto Maria Villa, Federica Malighetti, Matteo Villa, Luca Sala, Andrea Aroldi, Rocco Piazza, Diego Cortinovis, Luca Mologni, Daniele Ramazzotti

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

    Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies by Federica Malighetti, Matteo Villa, Mario Mauri, Simone Piane, Valentina Crippa, Ilaria Crespiatico, Federica Cocito, Elisa Bossi, Carolina Steidl, Ivan Civettini, Chiara Scollo, Daniele Ramazzotti, Carlo Gambacorti-Passerini, Rocco Piazza, Luca Mologni, Andrea Aroldi

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: